Emerging treatments
Tumour necrosis factor inhibitors
European League Against Rheumatism/ American College of Rheumatology guidelines have strongly recommended against the use of tumour necrosis factor inhibitors, citing absence of evidence for benefit, increased potential adverse effects, and significant cost.[45]
Hydroxychloroquine
Very limited data have suggested benefit with hydroxychloroquine in patients who experience adverse effects to corticosteroids, but this is not standard therapy.[58]
Use of this content is subject to our disclaimer